Business Description
Nykode Therapeutics AS
ISIN : NO0010714785
Share Class Description:
FRA:5VB: Ordinary SharesTotal Employee Number:
57Description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 21.99 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.14 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33.9 | |||||
3-Year EPS without NRI Growth Rate | 35.2 | |||||
3-Year FCF Growth Rate | -4.7 | |||||
3-Year Book Growth Rate | -18.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.44 | |||||
9-Day RSI | 45.93 | |||||
14-Day RSI | 47.12 | |||||
3-1 Month Momentum % | 16.52 | |||||
6-1 Month Momentum % | 72.31 | |||||
12-1 Month Momentum % | 121.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.66 | |||||
Quick Ratio | 12.66 | |||||
Cash Ratio | 11.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 35.29 | |||||
5-Year Yield-on-Cost % | 35.29 | |||||
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 32.34 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -14.2 | |||||
ROA % | -13.11 | |||||
ROIC % | -53.75 | |||||
3-Year ROIIC % | 7445.47 | |||||
ROC (Joel Greenblatt) % | -291 | |||||
ROCE % | -16.79 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.25 | |||||
Price-to-Tangible-Book | 1.23 | |||||
EV-to-EBIT | -3.18 | |||||
EV-to-EBITDA | -3.6 | |||||
EV-to-Forward-Revenue | 0.02 | |||||
EV-to-FCF | -2.03 | |||||
Price-to-GF-Value | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.45 | |||||
Earnings Yield (Greenblatt) % | -31.45 | |||||
FCF Yield % | -26.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nykode Therapeutics AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.035 | ||
| Beta | 1.3184 | ||
| 3-Year Sharpe Ratio | -0.27 | ||
| 3-Year Sortino Ratio | -0.43 | ||
| Volatility % | 138.02 | ||
| 14-Day RSI | 47.12 | ||
| 14-Day ATR (€) | 0.01171 | ||
| 20-Day SMA (€) | 0.25565 | ||
| 12-1 Month Momentum % | 121.71 | ||
| 52-Week Range (€) | 0.0859 - 0.357 | ||
| Shares Outstanding (Mil) | 326.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nykode Therapeutics AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nykode Therapeutics AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-25 | In 150 days | ||
| Third quarter earnings results for 2026 | 2026-11-25 | In 150 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-26 | In 59 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 59 days | ||
| First quarter earnings conference call for 2026 | 2026-05-27 15:00 | 0.26 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 0.26 (+0.00%) | ||
| General meeting for 2026 | 2026-05-13 10:00 | 0.25 (+0.00%) | ||
| Annual report for 2025 | 2026-04-17 | 0.25 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 09:00 | 0.28 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 0.28 (+0.00%) |
Show
Entries
Nykode Therapeutics AS Frequently Asked Questions
What is Nykode Therapeutics AS(FRA:5VB)'s stock price today?
The current price of FRA:5VB is €0.25. The 52 week high of FRA:5VB is €0.36 and 52 week low is €0.09.
When is next earnings date of Nykode Therapeutics AS(FRA:5VB)?
The next earnings date of Nykode Therapeutics AS(FRA:5VB) is 2026-08-26.
Does Nykode Therapeutics AS(FRA:5VB) pay dividends? If so, how much?
The Dividend Yield %  of Nykode Therapeutics AS(FRA:5VB) is 35.29% (As of Today), Highest Dividend Payout Ratio of Nykode Therapeutics AS(FRA:5VB) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Nykode Therapeutics AS(FRA:5VB) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| BioConnection to manufacture clinical trial material for Nykode Therapeutics' vaccine | 2021-11-29 |
Articles on Nykode Therapeutics AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers